<SEC-DOCUMENT>0000899243-16-012604.txt : 20160203
<SEC-HEADER>0000899243-16-012604.hdr.sgml : 20160203
<ACCEPTANCE-DATETIME>20160203070033
ACCESSION NUMBER:		0000899243-16-012604
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160201
FILED AS OF DATE:		20160203
DATE AS OF CHANGE:		20160203

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALNYLAM PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001178670
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770602661
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		300 THIRD STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		(617) 551-8200

	MAIL ADDRESS:	
		STREET 1:		300 THIRD STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALNYLAM PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20020724

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36407
		FILM NUMBER:		161383118

	BUSINESS ADDRESS:	
		STREET 1:		54 RUE LA BOETIE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75008
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		54 RUE LA BOETIE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75008

	FORMER NAME:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER NAME:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2016-02-01</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001178670</issuerCik>
        <issuerName>ALNYLAM PHARMACEUTICALS, INC.</issuerName>
        <issuerTradingSymbol>ALNY</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001121404</rptOwnerCik>
            <rptOwnerName>Sanofi</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>54 RUE LA BOETIE</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>PARIS</rptOwnerCity>
            <rptOwnerState>I0</rptOwnerState>
            <rptOwnerZipCode>75008</rptOwnerZipCode>
            <rptOwnerStateDescription>FRANCE</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2016-02-01</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>205030</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>69.75</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>10256633</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>Via wholly-owned subsidiary, Genzyme Corp.</value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Purchase of shares in accordance with the terms of the investor agreement between Alnylam and Genzyme (a Sanofi company) dated February 27, 2014.</footnote>
    </footnotes>

    <remarks>Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Alexandra Roger, Head of Securities Law and Capital Markets</signatureName>
        <signatureDate>2016-02-03</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>attachment1.htm
<DESCRIPTION>EX-24 DOCUMENT
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY>
<PRE>
                                POWER OF ATTORNEY

        The undersigned, Sanofi, a societe anonyme organized under the laws of
France (hereinafter referred to as the "Company") does hereby make, constitute
and appoint each of the persons listed below as the Company's true and lawful
agent and attorney-in-fact (hereinafter referred to as the "Attorney") to act
either together or alone in the name and on behalf of the Company for and with
respect to the matters hereinafter described.

            Name of Attorney:

            Claire Terrazas

            Alexandra Roger


        Each Attorney shall have the power and authority to execute and deliver
any Form ID, Schedule 13D, Schedule 13G or Forms 3, 4 and 5 or any amendments
thereto required to be filed with the Securities and Exchange Commission under
the Securities Exchange Act of 1934 on behalf of the Company with regard to any
securities owned by the Company or any of its subsidiaries; and, in connection
with the foregoing, to execute and deliver all documents, acknowledgments,
consents and other agreements and to take such further action as may be
necessary or convenient for the Company in order to more effectively carry out
the intent and purpose of the foregoing.

        Agreements, commitments, documents, instruments and other writings
executed by the Attorney in accordance with the terms hereof shall be binding
upon the Company without attestation and without affixation of the seal of the
Company. The Power of Attorney conferred hereby shall not be delegable by any
Attorney. The Attorney shall serve without compensation for acting in the
capacity of agent and attorney-in-fact hereunder.

        Unless revoked by the Company, this appointment contained hereof shall
in all circumstances remain in force and be irrevocable until such time as the
Attorney ceases to be an employee of the Company, but shall be of no further
effect after that date.

        IN WITNESS WHEREOF, the Company has caused the Power of Attorney to be
executed, attested and its corporate seal to be affixed as of the 28th day of
January, 2016.


                                        Sanofi

                                        By:/s/ Karen Linehan
                                           -----------------
                                           Karen Linehan
                                           Executive Vice President, Legal
                                           Affairs and General Counsel
</PRE>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
